These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 16927388)

  • 1. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
    Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions.
    Yonou H; Ochiai A; Goya M; Kanomata N; Hokama S; Morozumi M; Sugaya K; Hatano T; Ogawa Y
    Prostate; 2004 Mar; 58(4):406-13. PubMed ID: 14968441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism.
    Yonou H; Aoyagi Y; Kanomata N; Kamijo T; Oda T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Biochem Biophys Res Commun; 2001 Dec; 289(5):1082-7. PubMed ID: 11741302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
    Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin in prostate cancer bone metastasis.
    Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
    Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
    Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
    Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.
    Yang J; Fizazi K; Peleg S; Sikes CR; Raymond AK; Jamal N; Hu M; Olive M; Martinez LA; Wood CG; Logothetis CJ; Karsenty G; Navone NM
    Cancer Res; 2001 Jul; 61(14):5652-9. PubMed ID: 11454720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mechanism of osteoblastic bone metastasis of prostate cancer].
    Yonou H; Ogawa Y; Ochiai A
    Clin Calcium; 2006 Apr; 16(4):557- 64. PubMed ID: 16582505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
    Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
    Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
    J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
    Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
    Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
    Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone.
    Yonou H; Yokose T; Kamijo T; Kanomata N; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2001 Mar; 61(5):2177-82. PubMed ID: 11280783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
    Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss.
    Wakchoure S; Swain TM; Hentunen TA; Bauskin AR; Brown DA; Breit SN; Vuopala KS; Harris KW; Selander KS
    Prostate; 2009 May; 69(6):652-61. PubMed ID: 19152406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.